1332524-01-2

Basic information

• Product Name: N-[3-Fluoro-4-[(methylamino)carbonyl]phenyl]-2-methylalanine methyl ester
• Synonyms: N-[3-Fluoro-4-[(methylamino)carbonyl]phenyl]-2-methylalanine methyl ester;Alanine, N-[3-fluoro-4-[(MethylaMino)carbonyl]phenyl]-2-Methyl-, Methyl ester;Methyl 2-((3-fluoro-4-(MethylcarbaMoyl)phenyl)aMino)-2-Methylpropanoate;N-[3-fluoro-4-[(MethylaMino)carbonyl]phenyl]-2-Methyl-Alanine Methyl ester 2-(3-Fluoro-4-MethylcarbaMoyl-phenylaMino)-2-Methyl-propionic acid Methyl ester ";2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methylpropanoate methyl;NN-[3-Fluoro-4-[(methylamino)carbonyl]phenyl]-2-methylalanine methyl ester;methyl 2-[3-fluoro-4-(methylcarbamoyl)anilino]-2-methyl-propanoat e
• CAS NO: 1332524-01-2
• Molecular Formula: C₁₃H₁₇FN₂O₃
• Molecular Weight: 268.2840832
• Mol File: 1332524-01-2.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 381℃
• Flash Point: 184℃
• Appearance: /
• Density: 1.203
• Solubility: Chloroform, DCM, Ethyl Acetate
• PKA: 14.35±0.46(Predicted)
• CAS DataBase Reference: N-[3-Fluoro-4-[(methylamino)carbonyl]phenyl]-2-methylalanine methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-[3-Fluoro-4-[(methylamino)carbonyl]phenyl]-2-methylalanine methyl ester(1332524-01-2)
• EPA Substance Registry System: N-[3-Fluoro-4-[(methylamino)carbonyl]phenyl]-2-methylalanine methyl ester(1332524-01-2)

Safety Data

• Hazardous Substances Data: 1332524-01-2(Hazardous Substances Data)

Usage

Uses

N-[3-Fluoro-4-[(methylamino)carbonyl]phenyl]-2-methylalanine Methyl Ester is an intermediate in the synthesis of MDV 3100 (M199800), is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex.

Upstream product

• 67-56-1 methanol 
• 1289942-66-0 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methyl propanoic acid 
• 749927-69-3 4-bromo-2-fluoro-N-methylbenzanamide 
• 151982-51-3 4-bromo-2-fluorobenzoyl chloride 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 915087-33-1 enzalutamide 
• 1242137-15-0 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-imidazolidinethione-1-yl)-2-fluorobenzoic acid 

Relevant articles and documents

Preparation method of enzalutamide intermediate

The invention provides a preparation method of an enzalutamide intermediate (formula A). The R group is selected from C1-C4 alkyl, benzyl and phenyl groups, an intermediate (formula A) is synthesizedthrough the method and used for preparing enzalutamide, the reagents such as halogenated hydrocarbon with high toxicity are prevented for producing enzalutamide, meanwhile, by-product impurities generated due to use of inorganic base are avoided, and the yield and purity are high.

A "one-pot synthesis" method of synthesizing graciousness mixed Lu An

The invention provides a one-pot method for synthetizing enzalutamide and belongs to the field of medicinal chemical synthesis. The method comprises the following steps: firstly, carrying out copper-catalyzed Buchwald reaction on N-methyl-4-bromo-2-fluoro-benzamide and 2-methyl alanine, adding halogenated hydrocarbon, reacting to generate ester, finally adding a key intermediate 4-isothiocyano-2-(trifluoromethyl) cyanophenyl and carrying out bucherer-Bergs reaction to generate the enzalutamide. The method is simple in operation and high in product yield and has the advantages that the intermediate products are not needed to be separated and directly reacted, so that the process flow cycle is shortened; the final product is easy to separate and purify.

PROCESSES FOR THE SYNTHESIS OF DIARYLTHIOHYDANTOIN AND DIARYLHYDANTOIN COMPOUNDS

Processes are provided for the synthesis of diarylthiohydantoin and diarylhydantoin compounds, such as compounds of the formula: wherein X, Y1, Y2, R1, and R2 are as defined herein. Medicinal products containing the same find particular use in treating prostate cancer, including castration-resistant prostate cancer and/or hormone-sensitive prostate cancer.